Loading
ImmunoBlue is a Baltimore company that combines nanoparticles with immunotherapy to treat cancer, including a project to make T cells that recognise glioblastoma.
ImmunoBlue, LLC, of Baltimore, founded by its chief executive Rohan Fernandes, engineers nanoimmunotherapies that combine nanotechnology and immunotherapy to treat several types of cancer. In fiscal year 2026 the National Cancer Institute funded its STTR project on engineering glioblastoma-specific T cells using immunostimulatory photothermal nanoparticles (5R42CA287488-03, USD 1,106,515).
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR (R42) award 5R42CA287488-03: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Magnetic nanoparticle hyperthermia, Glioma & glioblastoma.
Shares Photothermal (plasmonic) nanoparticle ablation, Glioma & glioblastoma.
Shares Photothermal (plasmonic) nanoparticle ablation, Magnetic nanoparticle hyperthermia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/